The study aims to determine if RLS-0071 is safe and effective for treating this condition. Patients will receive different doses of RLS-0071 over a period of up to 14 days. Some patients will also receive another medication called ruxolitinib as part of their treatment. The treatment will be given to patients while they are in the hospital.

During the study, doctors will monitor how well patients respond to the treatment by checking their symptoms, particularly those affecting the skin, liver, and digestive system. They will also track changes in the patients’ condition for up to 180 days after starting treatment. The study will measure various aspects of patient recovery, including pain levels, ability to eat, and overall well-being.

The main purpose of this research is to determine if RLS-0071 is safe and effective for treating steroid-resistant acute graft versus host disease. The medication will be tested at different dose levels to find the most appropriate dosing. During the study, participants will receive RLS-0071 infusions for up to 14 days while in the hospital.

Throughout the study, doctors will monitor how well the treatment works by checking the condition of affected organs, including the skin, liver, and digestive system. They will also track various health measurements and collect blood samples to understand how the medication works in the body. The total duration of monitoring after treatment will be 180 days to evaluate long-term effects of the medication.

Participants in this study will continue their treatment with ruxolitinib or its combinations as they have been doing in their previous studies. The study will monitor the frequency and severity of any side effects or adverse events that occur during the treatment. This information will help researchers understand the long-term safety of these medications and their combinations.

The study is open-label, meaning that both the participants and the researchers know which treatment is being administered. It is conducted at multiple centers, allowing for a diverse group of participants. The study aims to provide valuable data on the safety of these treatments, which can benefit future patients who may receive these medications. Participants will be assessed regularly to determine any clinical benefits they may experience from the continued treatment.

The study will use several medications including cyclophosphamide, mycophenolate mofetil, and tacrolimus. One group of patients will receive Grafalon, which contains antibodies that affect the immune system, while another group will receive a different combination of medications. These medications will be given through infusion into a vein or taken by mouth.

The treatment will be given around the time of the stem cell transplantation. Patients will receive their assigned medications according to a specific schedule, with some treatments lasting a few days and others continuing for several months. The medications are used to help the body accept the transplanted cells and prevent rejection.

The purpose of the study is to assess how safe and tolerable the ATreg treatment is for patients. Participants in the study will receive the ATreg treatment through an infusion, which is a method of delivering medication directly into the bloodstream. The study will monitor participants for any serious side effects related to the treatment at various intervals, including 24 hours, 3 days, 7 days, and 14 days after receiving the ATreg infusion. Additionally, the study will observe the effects of the treatment on the incidence and severity of acute GvHD, as well as any potential infections or relapses of the underlying blood cancer.

Throughout the study, researchers will also track changes in blood components such as neutrophils, platelets, and haemoglobin to assess how well the transplanted cells are taking hold in the body. The study will continue to monitor participants for up to six months after the ATreg treatment to gather comprehensive data on the treatment’s long-term effects, including any occurrences of GvHD, infections, or cancer relapse. This trial aims to provide valuable insights into the potential benefits and risks of using ATreg cells in patients who have recently undergone a stem cell transplant.

The purpose of the study is to see how well the new treatment works and how safe it is for patients with HR-aGvHD. Participants in the study will be randomly assigned to receive either the new treatment with corticosteroids or a placebo with corticosteroids. The study will monitor participants over a period of time to see how their condition responds to the treatment. The main goal is to observe the overall response of the disease by Day 28, which means checking if the symptoms have improved or resolved.

Throughout the study, researchers will also look at other important factors, such as how long the response lasts, overall survival, and any side effects that may occur. The study aims to provide valuable information that could lead to better treatment options for people with HR-aGvHD in the future.

The trial will involve the use of several medications. SOLUMEDROL, which contains the active ingredient methylprednisolone hemisuccinate, and CORTANCYL, which contains prednisone, are both corticosteroids used in the study. Additionally, Uvadex, containing methoxsalen, is used in conjunction with the ECP procedure. Another medication, Noxafil, which contains posaconazole, is also part of the study. The purpose of the study is to determine which treatment approach is more effective in preventing treatment failure, which means the disease does not worsen or require additional treatment, over a period of six months.

Participants in the study will be randomly assigned to one of the two treatment groups. The study will last for several months, during which patients will receive their assigned treatment and be monitored for any changes in their condition. The goal is to see how well each treatment works in managing the symptoms of acute GVHD and to assess the overall health and quality of life of the participants. The study will also track any side effects or complications that may arise during the treatment period.

The purpose of the study is to determine if MC0518 is more effective than the current best available treatments in improving the condition of patients with SR aGvHD. Participants in the study will receive either the MC0518 treatment or the best available therapy. The study will monitor the participants’ response to the treatment over a period of time, checking for improvements in their condition and overall survival.

Throughout the study, participants will be regularly assessed to track their progress and any changes in their health. The study aims to provide valuable information on the safety and effectiveness of MC0518 in treating SR aGvHD, potentially offering a new option for patients who do not respond to standard steroid treatments.

Participants in the study will receive either the new treatment or one of the existing therapies, which may include medications like infliximab, anti-T lymphocyte immunoglobulin (from rabbits), methoxsalen, ruxolitinib, or etanercept. These treatments are administered in different ways, such as through intravenous infusion or oral intake, depending on the specific medication. The purpose of the study is to evaluate how well these treatments work in improving the condition by assessing the overall response rate at specific intervals, such as 28 days after starting the treatment.

The trial will follow participants over a period of time to monitor their response to the treatment, any side effects, and overall health outcomes. The study aims to provide valuable information on the best treatment options for children and adolescents with SR aGvHD, potentially improving their quality of life and long-term health. Participants will be closely monitored by healthcare professionals throughout the study to ensure their safety and well-being.